Percentage of human PD-1+CD8+ T cell populations was significantly lower in AMSC-treated mice than in GVHD controls at weeks 2 and 3 (P < 0.01 and P < 0.05, respectively), although the difference was not significant between AMSC and BMSC treatment in this regard. Here, CD8A is linked to graft versus host disease.